酰coa:胆固醇酰基转移酶抑制剂avasimibe降低动脉粥样硬化除了其降胆固醇效果的载脂蛋白e * 3-Leiden老鼠。
文章的细节
-
引用
复制到剪贴板 -
Delsing DJ, Offerman嗯,范Duyvenvoorde W, van Der繁荣H, de智慧EC Gijbels MJ, van Der Laarse, Jukema JW, Havekes LM, Princen嗯
酰coa:胆固醇酰基转移酶抑制剂avasimibe降低动脉粥样硬化除了其降胆固醇效果的载脂蛋白e * 3-Leiden老鼠。
循环。2001年4月3日,103 (13):1778 - 86。
- PubMed ID
-
11282910 (在PubMed]
- 文摘
-
背景:本研究调查是否ACAT抑制剂avasimibe可以减少动脉粥样化形成独立的降胆固醇作用的载脂蛋白e * 3-Leiden老鼠。方法和结果:两组15女性ApoE * 3-Leiden老鼠放在一个高胆固醇饮食(HC);1组0.01% (wt / wt) avasimibe混合进饮食。HC饮食导致血浆胆固醇浓度为18.7 + / - -2.6更易与L。添加avasimibe血浆胆固醇下降了56%,至8.1 + / - -1.2更易与L,主要是通过减少和组成变化导致VLDL和低密度脂蛋白。在一个单独的低胆固醇(LC)对照组,血浆胆固醇被滴定的水平与avasimibe集团(10.3 + / - -1.4更易/ L)通过降低膳食胆固醇的数量。22周的干预后,动脉粥样硬化在主动脉根区域量化。avasimibe导致治疗减少了92%的病变区域与HC对照组相比。与LC控制相比,avasimibe病变面积减少了78%。修正后LC之间的细微差别,胆固醇曝光控制和avasimibe组,avasimibe在病变区域的影响(减少73%)仍然非常重要。 In addition, monocyte adherence to the endothelium, free cholesterol accumulation, and lesion severity were reduced by avasimibe treatment. CONCLUSIONS: Treatment with avasimibe potently lowered plasma cholesterol levels in ApoE*3-Leiden mice and considerably reduced atherosclerotic lesion area in addition to its cholesterol-lowering effect. Because monocyte adherence to the endothelium and lesion severity were also reduced by avasimibe, treatment with avasimibe may result in higher plaque stability and therefore a reduced risk of plaque rupture.